Literature DB >> 3816954

Competitive interaction of pirenzepine with rat brain muscarinic acetylcholine receptors.

E E el-Fakahany, C L Cioffi, M M Abdellatif, M M Miller.   

Abstract

In the present work, we studied the details of the interaction of the nonclassical muscarinic receptor antagonist pirenzepine with [3H]quinuclidinyl benzilate binding sites in rat brain homogenates. Pirenzepine showed biphasic competition curves with a Hill coefficient lower than unity, and these curves were better described according to a two-site receptor model. The affinities and the relative preponderance of these sites were constant at different ligand concentrations, in accordance with a competitive type of interaction. Similarly, pirenzepine did not influence the rate of dissociation of the [3H]quinuclidinyl benzilate-receptor complex, even at relatively high concentrations. However, although low concentrations of pirenzepine decreased the affinity of [3H]quinuclidinyl benzilate for the receptor without affecting the density of the binding sites, higher concentrations of the antagonist decreased the receptor number in a reversible fashion. Schild plots of these data indicated an apparent deviation from simple competition in this experimental design, an observation which can be attributed to the selectivity of pirenzepine for different receptor subtypes. Furthermore, pirenzepine, at concentrations high enough to saturate both its high- and low-affinity sites protected [3H]quinuclidinyl benzilate binding sites in the brain against irreversible alkylation by propylbenzilylcholine mustard. Therefore, our data support a competitive nature of interaction of pirenzepine with rat brain muscarinic receptors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3816954     DOI: 10.1016/0014-2999(86)90577-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Dose-dependent effects of repeated ketamine administration on muscarinic acetylcholine receptors in the mouse forebrain.

Authors:  Shinichiro Hitomi; Toshihito Morita; Shigeru Saito; Yoshitaka Uchihashi
Journal:  J Anesth       Date:  1995-09       Impact factor: 2.078

2.  Effects of aging on the interaction of quinuclidinyl benzilate, N-methylscopolamine, pirenzepine, and gallamine with brain muscarinic receptors.

Authors:  W Surichamorn; O N Kim; N H Lee; W S Lai; E E el-Fakahany
Journal:  Neurochem Res       Date:  1988-12       Impact factor: 3.996

3.  Selectivity of oxomemazine for the M1 muscarinic receptors.

Authors:  S W Lee; C W Woo; J G Kim
Journal:  Arch Pharm Res       Date:  1994-12       Impact factor: 4.946

4.  Repeated ketamine administration produces up-regulation of muscarinic acetylcholine receptors in the forebrain, and reduces behavioral sensitivity to scopolamine in mice.

Authors:  T Morita; S Hitomi; S Saito; T Fujita; Y Uchihashi; H Kuribara
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.